508 filings
Page 8 of 26
8-K
cmtm7v9mf1fb3t qheo4
14 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
hz7mif7iysl0m7
8 Feb 18
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
12:00am
CT ORDER
z3ps2pjm 47jyj38m
24 Jan 18
Confidential treatment order
12:00am
CT ORDER
vkiareq6x7hgssa3l1rj
24 Jan 18
Confidential treatment order
12:00am
UPLOAD
lb9 w8l7hnp
23 Jan 18
Letter from SEC
12:00am
CORRESP
4qc38gf 0v4p
19 Jan 18
Correspondence with SEC
12:00am
UPLOAD
gzacp13
10 Jan 18
Letter from SEC
12:00am
8-K
86tdo1 bmogdli9dp6
8 Jan 18
Alnylam Announces 2018 Corporate Goals
12:00am
8-K
cfxafgjo 0884whwpk
3 Jan 18
Other Events
12:00am
CORRESP
rk72rv jqi9fcoaqi
11 Dec 17
Correspondence with SEC
12:00am
UPLOAD
i5py42 qe
28 Nov 17
Letter from SEC
12:00am
424B5
70ojsf5 veblmt5z
14 Nov 17
Prospectus supplement for primary offering
12:00am
8-K
t71jsmo 27
14 Nov 17
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
12:00am
424B5
v0f1dhy ubd3
13 Nov 17
Prospectus supplement for primary offering
12:00am
8-K
yjr9p
7 Nov 17
Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity
12:00am
CT ORDER
zdzr0hg2y88jicmog dm
24 Oct 17
Confidential treatment order
12:00am
CT ORDER
835ychkhpqi09ftp
12 Sep 17
Confidential treatment order
12:00am
8-K
jsr8y2n
7 Sep 17
Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs
12:00am